专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130190363A1 THERAPEUTIC AGENT FOR NEUROLOGICAL DISEASES 有权
标题翻译：神经病变治疗药物
公开(公告)号：US20130190363A1
公开(公告)日：2013-07-25
申请号：US13812726
申请日：2011-07-15
申请人： Joh-E Ikeda , Noriaki Hirayama , Satoshi Inoue , Kazunori Tanaka , Takuya Kanno
发明人： Joh-E Ikeda , Noriaki Hirayama , Satoshi Inoue , Kazunori Tanaka , Takuya Kanno
IPC分类号： C07D401/04 , C07D233/88
CPC分类号： C07D401/04 , C07D233/88
摘要： An object of the present invention is to provide a pharmaceutical agent useful for treating and preventing neurological disease, having satisfactory solubility and oxidative stress-mediated cell death suppressive activity as well as capable of exhibiting excellent blood-brain barrier permeability. The present invention is directed to an acylaminoimidazole derivative represented by general formula (I) or a salt thereof, and a pharmaceutical and a therapeutic or preventive agent for neurological disease containing the same, as an active ingredient.
摘要翻译：本发明的目的是提供一种可用于治疗和预防神经疾病，具有令人满意的溶解性和氧化应激介导的细胞死亡抑制活性以及能够表现出优异的血脑屏障通透性的药剂。本发明涉及由通式（I）表示的酰基氨基咪唑衍生物或其盐，以及含有该酰基氨基咪唑衍生物作为有效成分的药物及其神经病学治疗或预防剂。

2. 发明授权

US08975411B2 Therapeutic agent for neurological diseases 有权
标题翻译：神经系统疾病治疗剂
公开(公告)号：US08975411B2
公开(公告)日：2015-03-10
申请号：US13812726
申请日：2011-07-15
申请人： Joh-E Ikeda , Noriaki Hirayama , Satoshi Inoue , Kazunori Tanaka , Takuya Kanno
发明人： Joh-E Ikeda , Noriaki Hirayama , Satoshi Inoue , Kazunori Tanaka , Takuya Kanno
IPC分类号： C07D401/04 , C07D401/14 , C07D217/00 , C07D217/02 , C07D233/00 , C07D233/88
CPC分类号： C07D401/04 , C07D233/88
摘要： An object of the present invention is to provide a pharmaceutical agent useful for treating and preventing neurological disease, having satisfactory solubility and oxidative stress-mediated cell death suppressive activity as well as capable of exhibiting excellent blood-brain barrier permeability. The present invention is directed to an acylaminoimidazole derivative represented by general formula (I) or a salt thereof, and a pharmaceutical and a therapeutic or preventive agent for neurological disease containing the same, as an active ingredient.
摘要翻译：本发明的目的是提供一种可用于治疗和预防神经疾病，具有令人满意的溶解性和氧化应激介导的细胞死亡抑制活性以及能够表现出优异的血脑屏障通透性的药剂。本发明涉及由通式（I）表示的酰基氨基咪唑衍生物或其盐，以及含有该酰基氨基咪唑衍生物作为有效成分的药物及其神经病学治疗或预防剂。

3. 发明申请

US20110105517A1 THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS 审中-公开
标题翻译：治疗前列腺癌的治疗药物
公开(公告)号：US20110105517A1
公开(公告)日：2011-05-05
申请号：US13001871
申请日：2009-06-16
申请人： Joh-E Ikeda , Hitoshi Osuga , Kazunori Tanaka
发明人： Joh-E Ikeda , Hitoshi Osuga , Kazunori Tanaka
IPC分类号： A61K31/4985 , A61P25/28 , A61P25/00
CPC分类号： A61K31/4985 , C07D519/00
摘要： Disclosed is a safe and effective therapeutic agent that can alleviate the symptoms of the intractable disease ALS and slow the progress thereof. The therapeutic agent for amyotrophic lateral sclerosis contains bromocriptine or a pharmaceutically acceptable salt thereof as the active ingredient.
摘要翻译：公开了一种安全有效的治疗剂，其可以缓解顽固性疾病ALS的症状并减慢其进展。用于肌萎缩性侧索硬化症的治疗剂包含溴隐亭或其药学上可接受的盐作为活性成分。

4. 发明授权

US06429011B1 Neuronal apoptosis inhibitor protein gene sequence and mutations causative of spinal muscular atrophy 失效
标题翻译：神经元凋亡抑制蛋白基因序列和突变导致脊髓性肌萎缩
公开(公告)号：US06429011B1
公开(公告)日：2002-08-06
申请号：US09493784
申请日：2000-01-28
申请人： Alex E. MacKenzie , Robert G. Korneluk , Natalie Roy , Mani S. Mahadevan , Michael McLean , Joh-E Ikeda
发明人： Alex E. MacKenzie , Robert G. Korneluk , Natalie Roy , Mani S. Mahadevan , Michael McLean , Joh-E Ikeda
IPC分类号： C12N1574
CPC分类号： C07K14/4747 , C12Q1/6883 , G01N33/6896
摘要： The gene for autosomal recessive neurodegenerative disorder Spinal Muscular Atrophy has been mapped to a region of chromosome 5. The gene encodes a protein having homology with apoptosis inhibitor proteins of viruses so that the encoded protein has been labelled as a neuronal apoptosis inhibitor protein (NAIP). A deletion in the (NAIP) domain was identified in persons with Type I, II and III Spinal Muscular Atrophy (SMA) and not in the normal non-SMA population.
摘要翻译：常染色体隐性遗传性神经退行性疾病的基因脊髓性肌肉萎缩已经映射到染色体5的一个区域。该基因编码与病毒的凋亡抑制蛋白具有同源性的蛋白质，使得编码的蛋白质被标记为神经元凋亡抑制蛋白（NAIP）。在I型，II型和III型脊髓性肌萎缩（SMA）患者中鉴定出（NAIP）域中的缺失，而不在正常非SMA群体中。

5. 发明申请

US20050100997A1 Apoptosis inhibitory protein, gene encoding the protein and cDNA thereof 审中-公开
标题翻译：细胞凋亡抑制蛋白，编码蛋白质和cDNA的基因
公开(公告)号：US20050100997A1
公开(公告)日：2005-05-12
申请号：US10628324
申请日：2003-07-29
申请人： Joh-E Ikeda , Kenji Yamamoto
发明人： Joh-E Ikeda , Kenji Yamamoto
IPC分类号： C07K14/47 , C12N9/99 , C07H21/04 , C07K16/40
CPC分类号： C07K14/4747
摘要： Novel apoptosis inhibitory proteins, a gene encoding the proteins and the cDNAs thereof are provided. More particularly, human apoptosis inhibitory proteins comprising the amino acid sequence of SQ ID No.1 or 3, a human gene encoding the human apoptosis inhibitory proteins and the cDNAs of the human gene comprising at least the nucleotide sequence for the coding region of SQ ID No.2 or 4, are provided.
摘要翻译：提供了新的凋亡抑制蛋白，编码蛋白质的基因及其cDNA。更具体地说，包含SQ ID No.1或3的氨基酸序列的人细胞凋亡抑制蛋白质，编码人细胞凋亡抑制蛋白质的人基因和至少包含SQID编码区域的核苷酸序列的人基因的cDNA 提供2或4。

6. 发明授权

US06617429B1 Apoptosis inhibitory protein, gene encoding the protein and cDNA thereof 失效
标题翻译：细胞凋亡抑制蛋白，编码蛋白质和cDNA的基因
公开(公告)号：US06617429B1
公开(公告)日：2003-09-09
申请号：US09705872
申请日：2000-11-06
申请人： Joh-E Ikeda , Kenji Yamamoto
发明人： Joh-E Ikeda , Kenji Yamamoto
IPC分类号： C07K1400
CPC分类号： C07K14/4747
摘要： Novel apoptosis inhibitory proteins, a gene encoding the proteins and the cDNAs thereof are provided. More particularly, human apoptosis inhibitory proteins comprising the amino acid sequence of SQ ID No.1 or 3, a human gene encoding the human apoptosis inhibitory proteins and the cDNAs of the human gene comprising at least the nucleotide sequence for the coding region of SQ ID No.2 or 4, are provided.
摘要翻译：提供了新的凋亡抑制蛋白，编码蛋白质的基因及其cDNA。更具体地说，包含SQ ID No.1或3的氨基酸序列的人细胞凋亡抑制蛋白质，编码人细胞凋亡抑制蛋白质的人基因和至少包含SQID编码区域的核苷酸序列的人基因的cDNA 提供2或4。

7. 发明授权

US5665572A Polymerase chain reaction amplification method using a single primer which randomly anneals 失效
标题翻译：聚合酶链反应扩增法使用单一引物随机退火
公开(公告)号：US5665572A
公开(公告)日：1997-09-09
申请号：US294606
申请日：1994-08-23
申请人： Joh-E Ikeda , Shinji Hadano , Haruhiko Yokoi
发明人： Joh-E Ikeda , Shinji Hadano , Haruhiko Yokoi
IPC分类号： C12Q1/68 , C12P19/34 , C07H21/02 , C07H21/04
CPC分类号： C12Q1/6832 , C12Q1/686
摘要： A method of amplifying template DNA by polymerase chain reaction (PCR) in which a single oligonucleotide primer having a restriction site is contacted with the template DNA, whereby the oligonucleotide randomly anneals to a single strand of the template DNA and DNA sequences complementary to the single strand are synthesized. An initial PCR amplification yields synthetic DNA sequences having the oligonucleotide sequence incorporated therein at the 5' end, and a sequence complementary to the template DNA. A second PCR amplification under higher stringency conditions amplifies regions of the template DNA to give DNA fragments having the restriction sites of the oligonucleotide primer. Thereby the method can be used to amplify trace quantities of template DNA of unknown sequence simply and efficiently, which has applications in the construction of DNA libraries of chromosome specific regions and the development of probes for chromosome mapping.
摘要翻译：通过聚合酶链式反应（PCR）扩增模板DNA的方法，其中将具有限制性位点的单个寡核苷酸引物与模板DNA接触，由此寡核苷酸随机退火到模板DNA的单链和与该单链互补的DNA序列链合成。初始PCR扩增产生在5'末端具有掺入寡核苷酸序列的合成DNA序列和与模板DNA互补的序列。在较高严格条件下的第二次PCR扩增扩增模板DNA的区域，得到具有寡核苷酸引物限制性位点的DNA片段。因此该方法可用于简单高效地扩增未知序列的痕量模板DNA，可用于构建染色体特异性区DNA文库，并开发用于染色体定位的探针。

8. 发明申请

US20050261306A1 Anti-neurodegenerative agents 审中-公开
公开(公告)号：US20050261306A1
公开(公告)日：2005-11-24
申请号：US11091928
申请日：2005-03-29
申请人： Joh-E Ikeda , Yoshinori Okada , Harumi Sakai , Hitoshi Osuga
发明人： Joh-E Ikeda , Yoshinori Okada , Harumi Sakai , Hitoshi Osuga
IPC分类号： C07D295/14 , A61K31/454 , A61K31/495 , A61K31/496 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/28 , C07D413/04 , C07D471/04 , A61K31/135 , A61K31/16 , A61K31/4747
CPC分类号： C07D471/04 , A61K31/454 , A61K31/495 , A61K31/496
摘要： The present invention provides methods for treating or preventing neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), Huntington's disease, Parkinson's disease, Alzheimer's disease, dementia after cerebral vascular disorder, dementia accompanied by other neuronal degeneration. The present invention provides methods for treating or preventing neurodegenerative diseases comprising administering a compound that upregulates neuronal apoptosis inhibitory protein (NAIP) production. Furthermore, the present invention provides methods for treating or preventing neurodegenerative diseases comprising administering one or more compounds selected from the group consisting of: 3-[4-(4-chlorophenyl) piperazin-1-yl] methyl]-1H-pyrrolo [2,3-b] pyridine or salts thereof 5-(4-chlorophenyl)-4-methyl-3-(1-(2-phenylethyl) piperidin-4-yl) isoxazole or salts thereof, 3-(4-chlorophenyl)-4-methyl-5-(1-(2-phenylethyl) piperidin-4-yl) isoxazole or salts thereof, N-methyl-4-(2-cyanophenyl) piperazinyl-3-methylbenzamine or salts thereof, 8-[(2,3-Dihydo-1,4-benzodioxin-2-yl)methyl]-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one or salts thereof, (E)-N-[(4-Hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide or salts thereof, (Z)-N-[(4-Hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide or salts thereof, an 5-[[4-[(1-Methylcyclohexyl)methoxy]phenyl]methyl]-2,4-thiazolidinedione or salts thereof. Moreover, the present invention provides methods of screening for an anti-neurodegenerative agent, comprising the steps of: (a) contacting a test sample with a cell and measuring NAIP production; and, (b) selecting a compound that increases the NAIP production in comparison with a control test in which the test sample is not contacted with the cell. Furthermore, the present invention provides compounds that upregulate NAIP production, wherein the compound can be isolated by the above screening method.

9. 发明授权

US6020127A Neuronal apoptosis inhibitor protein, gene sequence and mutations causative of spinal muscular atrophy 失效
标题翻译：神经元凋亡抑制蛋白，基因序列和脊髓性肌肉萎缩引起的突变
公开(公告)号：US6020127A
公开(公告)日：2000-02-01
申请号：US836134
申请日：1997-06-20
申请人： Alex E. MacKenzie , Robert G. Korneluk , Natalie Roy , Mani S. Mahadevan , Michael McLean , Joh-E Ikeda
发明人： Alex E. MacKenzie , Robert G. Korneluk , Natalie Roy , Mani S. Mahadevan , Michael McLean , Joh-E Ikeda
IPC分类号： G01N33/50 , C07K14/47 , C12N15/09 , C12N15/12 , C12Q1/68 , G01N33/566 , G01N33/68 , C07H21/04 , C12P19/34 , G01N33/53
CPC分类号： C07K14/4747 , G01N33/6896 , C12Q1/6883
摘要： The gene for the autosomal recessive neurodegenerative disorder Spinal Muscular Atrophy has been mapped to a region of chromosome 5. The gene encodes a protein having homology with apoptosis inhibitor proteins of viruses so that the encoded protein has been labelled as a neuronal apoptosis inhibitor protein (NAIP). A deletion in the (NAIP) domain was identified in persons with Type I, II and III Spinal Muscular Atrophy (SMA) and not in the normal non-SMA population.
摘要翻译： PCT No.PCT / CA95 / 00581 Sec。 371日期：1997年6月20日 102（e）日期1996年6月20日PCT提交1995年10月17日PCT公布。公开号WO96 / 12016 PCT 日期1996年4月25日常染色体隐性遗传性神经退行性疾病的基因脊髓性肌萎缩已被映射到染色体5的区域。该基因编码与病毒的凋亡抑制蛋白具有同源性的蛋白质，使得编码的蛋白质已被标记为神经元凋亡抑制蛋白（NAIP）。在I型，II型和III型脊髓性肌萎缩（SMA）患者中鉴定出（NAIP）域中的缺失，而不在正常非SMA群体中。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式